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Before 1990, most clinical isolates of
Streptococcus pneumoniae in the United States
were susceptible to a variety of antimicrobial
drugs, including penicillin (1,2). In the early
1990s, however, antimicrobial resistance began
to emerge (3-7), and ß-lactam resistance as a
result of altered penicillin binding proteins was
recognized (8-11). Resistance to other non-
ß-lactam drugs, such as the macrolides,
clindamycin, tetracycline, chloramphenicol, and
trimethoprim/sulfamethoxazole (TMP/SMX), be-
gan to increase (4-6). Therapeutic failures in
patients with pneumococcal infections treated
with previously effective drugs were reported (12).
During November 1994 through April 1995,
we assessed the prevalence of antimicrobial
resistance with S. pneumoniae at 30 U.S.
medical centers (4). Among 1,527 isolates of
S. pneumoniae, 14.1% had intermediate resis-
tance, and 9.5% were fully resistant to penicillin.
Aggregate rates of intermediate and high
penicillin resistance were 2.1% to 52.9%. In
addition, high rates of resistance were noted
with other antimicrobial drugs.
From November 1997 to April 1998, we
surveyed 34 U.S. medical centers to assess
changes in antimicrobial resistance rates with
S. pneumoniae during the 3 years since the 1994-
95 study. Twenty-four of these centers had also
participated in the earlier investigation. Similar
patient populations were sampled, and identical
test methods were used. In addition, we assessed
the relationship between various demographic
factors and resistance and undertook a
systematic analysis of multidrug resistance.
Finally, macrolide and fluoroquinolone resis-
tance was characterized at a molecular level.
The Study
From November 1, 1997, to April 30, 1998,
1,601 isolates of S. pneumoniae were recovered
in 34 U.S. medical centers. All isolates included
in this study were from consecutive patients.
With the exception of specimens from the lower
respiratory tract, all isolates were from normally
sterile body sites (i.e., blood, cerebrospinal fluid,
middle ear fluid, sinus aspirates, pericardial
fluid, and pleural fluid). Isolates from lower
respiratory tract specimens were included only if
they were of clinical significance.
In the study centers, isolates were subcul-
tured onto 5% sheep blood agar plates and
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incubated overnight at 35°C to 37°C in 5% to 7%
CO2. Colony growth was collected on a rayon
swab and immediately immersed in a transport
tube containing 12 ml of semisolid Ames
transport medium with charcoal (Difco Labora-
tories, Detroit, MI). Transport tubes were then
shipped overnight to the University of Iowa
College of Medicine for additional analysis
(Appendix). The recovery rate from this
transport system was 100%. Twelve concentra-
tions each of 23 antimicrobial drugs were tested
against 1,601 isolates of S. pneumoniae.
Overall, 17.4% of isolates had intermediate
and 12.1% had full resistance to penicillin (Table
1). Overall nonsusceptible rates with ceftriaxone
and cefuroxime (intermediate plus fully resistant)
Table 1. In vitro activity of 23 antimicrobial agents for 1,601 isolates of Streptococcus pneumoniae
Antimicrobial Penicillin-susceptible strains (n = 1,127) Penicillin-intermediate strains (n = 278)
agent MIC50 MIC90 MIC range % I % R MIC50 MIC90 MIC range % I % R
Penicillin     0.015       0.03   <0.004 - 0.06    --     --   0.5     1    0.12 - 1    --    --
Amoxicillin     0.015       0.03   <0.004 - 0.12   0.0   0.0   0.5     2    0.015 - 4 34.5 14
Amox/clav     0.015       0.03   <0.004 - 0.12   0.0   0.0   0.5     2    0.015 - 4 31.7 16.9
Ceftriaxone     0.015       0.03   <0.008 - 0.5   0.0   0.0   0.5     1    0.015 - 4 20.1   0.7
Cefuroxime     0.03        0.12   <0.015 - 2   0.2   0.1   2     4    0.12 - 8   6.8 55.8
Cefpodoxime     0.03        0.06   <0.015 - 4    –     –   1     4    0.03 - 8    --    --
Cefprozil     0.06        0.12   <0.03 - 1    –     –   2     8    0.06 - 16    –    –
Cefixime     0.25        0.5   <0.06 - 16    –     –   8   16    0.25 - 32    –    –
Loracarbef     0.5        1   <0.06 - 4    –     – 16 128    0.25 - >128    –    –
Cefaclor     0.5        2   <0.06 - 2    –     –   8   64    0.12 - >128    –    –
Ceftibuten     4        8   <0.25 - >64    –     – 64 >64    4 - >64    –    –
Clarithromycin   <0.03      <0.03   <0.03 - >64   0.5   5.2 <0.03 >64 <0.03 - >64   2.2 35.3
Erythromycin     0.06        0.06   <0.03 - >64   0.3   5.7    0.06 >64 <0.03 - >64   0.7 37.4
Azithromycin     0.06        0.12   <0.03 - >64   0.2   5.6    0.12 >64 <0.03 - >64   0.7 37.8
Clindamycin     0.06        0.06   <0.008 - >8   0.1   1.1    0.06   >8 <0.008 - 8   0.0 12.9
Trovafloxacin     0.06        0.12     0.015 - 8   0.0   0.2    0.06     0.12 0.015 - 0.25   0.0   0.0
Tetracycline     0.12        0.25   <0.03 - 64   0.2   2.5    0.25   32 <0.03 - >64   0.7 27.7
TMP/SMX     0.12        1     0.06 - 32   6.5   5.9    2     8 <0.03 - >32 19.8 42.4
Chloramphenicol     2        4   <0.5 - 16   –   0.8    4   16 <0.05 - 16    – 11.9
Rifampin   <0.12      <0.12   <0.12 - 0.5   0.0   0.0 <0.12   <0.12 <0.12 - 2   0.7   0.0
Linezolida     1        2      0.12 - 2   –     –   1     2    0.25 - 2    –    –
Quin/dalfo      0.25        0.5      0.06 - 8   0.0   0.2    0.25     0.5    0.06 - 1   0.0   0.0
Vancomycin      0.25        0.5      0.03 - 0.5   0.0   0.0    0.25     0.5    0.06 - 0.5   0.0   0.0
Antimicrobial Penicillin-resistant strains (n = 196) All strains (n = 1,601)
agent MIC50 MIC90 MIC range % I % R MIC50 MIC90 MIC range % I % R
Penicillin     2        4      2 - 8    --     --     0.015     2 <0.004 - 8 17.4 12.1
Amoxicillin     2        8      1 - 8   9.7   90.3     0.03     2 <0.004 - 8   7.2 13.5
Amox/clav     2        8      1 - 8   6.6   93.4     0.03     2 <0.004 - 8   6.3 14.4
Ceftriaxone     1        2      0.5 - 8 68.4   31.6     0.03     1 <0.008 - 8 10.9   4
Cefuroxime     4        8      2 - 32   0.0 100     0.03     4 <0.015 - 32   1.3 22
Cefpodoxime     4        8      1 - >32    --     --     0.06     4 <0.05 - >32    –    --
Cefprozil     8      16      2 - 64    –     –     0.12     8 <0.03 - 64    –    --
Cefixime   32      64      2 - 128    –     –     0.25   16 <0.06 - 128    –    --
Loracarbef 128 >128    32 - >128    –     –     1 128 <0.06 - >128    –    --
Cefaclor 128 >128    16 - >128    –     –     0.5   64 <0.06 - >128    –    --
Ceftibuten >64   >64   <16  - >64    –     –   44 >64 <0.25 - >64    –    –
Clarithromycin     2   >64   <0.03 - >64   3.6   64.8   <0.03     4 <0.03 - >64   1.2 17.7
Erythromycin     4   >64   <0.03 - >64   0.5   68.4     0.06     8 <0.03 - >64   0.4 18.9
Azithromycin     8   >64   <0.03 - >64   1.5   67.3     0.12   16 <0.03 - >64   0.4 18.7
Clindamycin      0.06     >8   <0.008 - >8   0.5   21.4     0.06     0.06 <0.008 - >8   0.1   5.6
Trovafloxacin      0.06       0.12     0.03 - 4   0.5     0.5     0.06     0.12    0.015 - 8   0.1   0.2
Tetracycline   16      32     0.06 - 64   0.5   51.5     0.12   16 <0.03 - >64   0.3 12.9
TMP/SMX     4      16     0.06 - 32 21.9   71.9     0.25     4 <0.03 - 32 10.7 20.4
Chloramphenicol     4      16   <0.5 - >16    –   37.2     2     4 <0.5 - >16    –   7.2
Rifampin   <0.12      <0.12   <0.12 - >4   0.0     0.5   <0.12   <0.12 <0.12 - >4   0.1   0.1
Linezolid     1        2     0.5 - 2    –     –     1     2    0.12 - 2   –    --
Quin/dalfo      0.25        0.5     0.12 1   0.0     0.0     0.25     0.5    0.06 - 8   0.0   0.1
Vancomycin      0.25        0.5     0.06 - 0.5   0.0     0.0     0.25     0.5    0.03 - 0.5   0.0   0.0
aBecause of the lack of NCCLS breakpoints for linezolid, resistance rates were not determined.
Amox/clav, amoxicillin/clavulanate; TMP/SMX, trimethoprim/sulfamethoxazole; Quin/dalfo, quinupristin/dalfopristin.
MIC, minimum inhibitory concentration; I, intermediate resistance; R, resistant.759 759 759 759 759 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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were 14.9% and 23.3%, respectively. Because
National Committee for Clinical Laboratory
Standards (NCCLS)-approved breakpoints are
lacking for the six other cephalosporins
examined in this study (cefpodoxime, cefixime,
ceftibuten, cefprozil, cefaclor, and loracarbef),
rates of resistance were not determined for these
drugs. However, when MIC values were
compared, cefpodoxime was the most active.
Comparison of MIC values of the three
macrolides we examined showed that clarithro-
mycin was consistently twice as active as
erythromycin, which in turn was consistently
twice as active as azithromycin (Table 1). Overall
rates of resistance, however, based on NCCLS
breakpoints, which differ for these agents, were
similar (18%-19%).
Compared with erythromycin as an indicator
of macrolide activity, 302 (18.9%) isolates had
MICs >1 µg/ml and thus were classified as
resistant (Table 1). Among these, 217 (71.9%)
had erythromycin MICs <32 µg/ml; the
remaining 85 strains (28.1%) had erythromycin
MICs  >64 µg/ml. Of the 217 strains with
erythromycin MICs <32, 214 had clindamycin
MICs  <0.25 and thus were categorized as
clindamycin susceptible. Thirty-five of these
strains, randomly selected, were examined by
polymerase chain reaction (PCR) for the
presence of ermAM and mefE genes. Of the 85
strains with erythromycin MICs >64 µg/ml, 83
had clindamycin MICs >8. Thirty-eight of these
isolates, chosen randomly, were ermAM positive;
12 were also positive for mefE (Table 2). Five
resistant strains were also characterized for the
presence of macrolide resistance determinants
(Table 2). Finally, the three isolates (Table 2)
negative for both the ermAM and mefE genes
were also negative by PCR for other known
determinants of macrolide/lincosamide resis-
tance in gram-positive bacteria (ermA, ermC,
ereA, ereB, msrA, and linA genes).
Of the 1,601 isolates examined, one had
intermediate resistance to trovafloxacin with an
MIC 2 µg/ml; three strains (0.2%) were
resistant, two with trovafloxacin MICs 4 µg/ml
and one with a trovafloxacin MIC 8 µg/ml. The
single strain with intermediate resistance had a
ciprofloxacin MIC of 16 and an asp83®tyr
substitution in the C subunit of topoisomerase
IV, as well as a ser84®tyr substitution in the A
subunit of DNA gyrase. The three trovafloxacin-
resistant strains had ciprofloxacin
MICs  >32 µg/ml and a ser79®phe substitution in
the C subunit of topoisomerase, as well as a
ser84®phe substitution in the A subunit of DNA
gyrase. None of these four strains had detectable
mutations in the QRDR of par E.
Overall rates of resistance, expressed as the
percentage of isolates intermediate or resistant,
for selected other agents are described in Table 1:
tetracycline, 13.2%, TMP/SMX, 31.1%, chloram-
phenicol, 7.2%, and rifampin, 0.2%. Linezolid
was uniformly active over a narrow range of
MICs (i.e., 0.12 to 2 µg/ml). Two strains among
the 1,601 examined in this study were resistant
to quinupristin/dalfopristin; one had an MIC
4 µg/ml and the other 8 µg/ml. Vancomycin was
uniformly active against the 1,601 isolates of
S. pneumoniae in this survey, with MICs
<0.5 µg/ml.
The in vitro activity of all ß-lactams
(penicillins, ß-lactamase inhibitor combinations
and cephalosporins), macrolides, clindamycin,
tetracycline, TMP/SMX, and chloramphenicol
was lowest with high-level penicillin-resistant
strains of S. pneumoniae and greatest with
penicillin-susceptible isolates. This trend was
not apparent with linezolid, trovafloxacin, rifampin,
quinupristin/dalfopristin, or vancomycin.
The prevalence of resistance to selected
agents was assessed according to the specimen
Table 2. Characterization of 302 Streptococcus
pneumoniae  isolates that were erythromycin resistant
(MICs  1> µg/ml)
Erythro-
mycin No. of No. with clindamycin MICs of
MIC  strains   0.25 0.5 1 2    8
11 5 1 5 a 000   0
25 2 5 1 b 000   1 c
45 3 5 3 d 000   0
86 8 6 8 e 000   0
16 23 22f 1g 00   0
32   6   5h 000   1 i
64 85   0 0 1j 1k 83l
aFour isolates characterized for ermAM and mefE; all four
ermAM-/mefE+.
bSeven isolates characterized; all seven ermAM-/mefE+.
cThis isolate was ermAM+/mefE-.
dSeven isolates characterized; one ermAM-/mefE-; six
ermAM-/mefE+.
eSeven isolates characterized; all seven ermAM-/mefE+.
fFour isolates characterized; all four ermAM-/mefE+.
gThis isolate was ermAM-/mefE-.
hThree isolates characterized; all ermAM-/mefE+.
iThis isolate was ermAM+/mefE-.
jThis isolate was ermAM-/mefE+.
kThis isolate was ermAM-/mefE-.
lThirty-eight of these isolates were characterized; 26 were
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source of isolates, the patient’s age, and the
health-care setting (Table 3). In general, the
highest resistance rates for all antimicrobial
drugs were observed in middle ear fluid and
sinus aspirate isolates and in isolates from
patients  <5 years old and from patients seen in
ambulatory-care settings.
When patterns of multidrug resistance were
analyzed, coresistance to penicillin, the macrolides,
tetracycline, TMP/SMX, and chloramphenicol
was observed in 5.4% of isolates (Table 4).
Resistance to the first four of these drugs but not
to chloramphenicol was seen with 3.7% of
strains. The most common pattern of multidrug
resistance (intermediate level or resistant to
penicillin and resistant to TMP/SMX, but
susceptible to the macrolides, tetracyclines, and
chloramphenicol) was observed in 6.9% of isolates.
In the 34 participating medical centers, the
lowest and highest overall rates of penicillin
resistance (intermediate plus resistant) were
12.8% and 64.6% (Table 5). Eight medical centers
had 10% to 18% penicillin resistance; 11 centers
had 19% to 26%; 5 had 27% to 36%; 7 had 37% to
Table 3. Recovery of Streptococcus pneumoniae strains with intermediate and high levels of resistance, by specimen
source and patient characteristics
No. (%) of resistant isolates for the following antimicrobial drugs
 Total no.   Penicillin Ceftriaxone Erythromycin Tetracycline  TMP/SMX  Chloramphenicol
Characteristic of isolates I R I R I R I R I R I R
Specimen sourcea
LRT 773 144 103   91   36 5 152 1 116   89 149 -- 67
(18.6) (13.3) (11.8) (4.7) (0.6) (20.9) (0.1) (15.0) (11.5) (19.3) (8.7)
Blood 509   68   41   35   16 1   59 2   33   40   87 -- 17
(13.4) (8.1) (6.9) (3.1) (0.2) (11.6) (0.4) (6.5) (7.9) (17.1) (3.3)
URT 238   50   48   44   11 0   77 2   53   28   74 -- 28
(21.0) (20.2) (18.5) (4.6) (0.0) (32.4) (0.8) (22.3) (11.8) (31.1) (11.8)
BF/CSF 60   12     3     4     1 0     9 0     3     1   13 --   2
(20.0) (5.0) (6.7) (1.7) (0.0) (15.0) (0.0) (5.0) (1.7) (21.7) (3.3)
Other 21     4     1     1     0 0     5 0     1     2     3) --   1
(19.0) (4.8) (4.8) (0.0) (0.0) (23.8) (0.0) (4.8) (9.5) (14.3) (4.8)
Age group (years)
<5 432   88   79   72   23 1 115 3   71   62 128 -- 42
(20.4) (18.3) (16.7) (5.3) (0.2) (26.6) (0.7) (16.4) (14.4) (29.6) (9.7)
6-20 97   14     6     6     1 0   12 0   11   11   14 --   4
(14.4) (6.2) (6.2) (1.0) (0.0) (12.4) (0.0) (11.3) (11.3) (14.4) (4.1)
21-50 407   76   42   39   18 2   71 0   56   32   80 -- 22
(18.7) (10.6) (9.6) (4.4) (0.5) (17.4) (0.0) (13.8) (7.9) (19.7) (5.4)
>50 652   96   68   57   22 3 102 2   66   65 102 -- 46
(14.7) (10.4) (8.7) (3.4) (0.5) (15.6) (0.3) (10.1) (10.0) (15.6) (7.1)
Service
Inpatient 969 172 111 104   37 3 171 3 107   85 192 -- 61
(17.8) (11.5) (10.7) (3.8) (0.3) (17.6) (0.3) (11.0) (8.8) (19.8) (6.3)
Outpatient 628 106   85   71   27  3 131 2   99   86 134 -- 54
(16.9) (13.5) (11.3) (4.3) (0.3) (20.9) (0.3) (15.8) (13.7) (21.3) (8.6)
aBF/CSF, body fluids/cerebrospinal fluid; LRT, lower respiratory tract; URT = upper respiratory tract.
TMP/SMX, trimethoprim/sulfamethoxazole.
Table 4. Frequency of isolation of strains of
Streptococcus pneumoniae with various patterns of
antimicrobial resistancea
Pattern of resistanceb
Peni- Erythro-  Tetra- TMP/ Chloram-
cillin   mycin cycline SMX  phenicol  No.
RS S S S   9 4
R S S R S 111
R S S R R     1
R S R S S     4
R S R R S     8
RS R R R   1 5
R R S S S     9
RR S R S   7 5
R R S R R     3
RR R S S   1 0
RR R R S   5 7
RR R R R   8 7
a Total number of isolates tested = 1,601.
bResistance includes both intermediate and resistant strains.
R, resistant; S, susceptible; TMP/SMX, trimethoprim/
sulfamethoxazole.
45%; 3 had >46%. Although no distinct
geographic clustering was identified, the highest
overall rates of penicillin resistance were in the761 761 761 761 761 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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Table 5. Resistance rates of selected antimicrobial drugs, by study center
Peni- Ceftria- Erythro- Tetra- Chloram- TMP/
No. of cillin xone mycin cycline phenicol SMX
Medical center and location isolates  % I % R % I % R % I % R % I % R % I % R % I % R
Children’s Hospital & Medical 50 26.0 12.0 10.0   8.0 0.0 30.0 0.0 24.0 -- 10.0   8.0 34.0
  Center, Seattle, WA
Veteran’s Affairs Medical Center, 24 12.5   4.2   8.3   0.0 0.0 12.5 0.0 12.5 --   0.0   4.2 25.0
  Portland, OR
UCSF Medical Center, 47   4.3   8.5   6.4   4.3 0.0 12.8 2.1 14.9 --   6.4   6.4 19.1
  San Francisco, CA
UCLA Medical Center, 55 27.3 14.5 20.0   1.8 1.8 18.2 0.0 20.0 -- 10.9 25.5 21.8
  Los Angeles, CA
Pathology Medical Laboratories, 51 15.7   2.0   3.9   0.0 0.0 13.7 0.0 11.8 --   2.0   9.8   9.8
  San Diego, CA
University of Utah Medical 53 13.2   9.4   9.4   1.9 0.0 17.0 0.0   7.5 –   5.7 13.2 20.8
  Center, Salt Lake City, UT
Denver Health, Denver, CO 26   7.7   7.7 11.5   0.0 0.0 7.7 0.0 11.5 -- 11.5   3.8 15.4
Good Samaritan Medical Center, 64 11.1 29.6 24.1 11.1 0.0 35.2 0.0 20.4 --   5.6 11.1 38.9
  Phoenix, AZ
University Hospital, 51 11.8   5.9   5.9   0.0 0.0 13.7 0.0   7.8 --   3.9   9.8 11.8
  Albuquerque, NM
Texas  Children’s Hospital, 48 39.6 25.0 26.0 10.4 0.0 43.8 2.1 22.9 -- 14.6 20.8 41.7
  Houston, TX
Parkland Health & Hospital 36 19.4 11.1 11.1   2.8 0.0 27.8 0.0 22.2 -- 11.1 16.7 22.2
  System, Dallas, TX
Mayo Clinic, Rochester, MN 48 16.7   6.3   6.3   4.2 0.0 20.8 2.1 10.4 --   6.3 10.4 16.7
University of Iowa Hospitals 49 16.3 22.4 16.3   4.1 0.0 22.4 0.0 20.4 -- 12.2 14.3 22.4
  and Clinics, Iowa City, IA
Children’s Hospital, Milwaukee, WI 55 12.7   7.3   7.3   3.6 0.0 10.9 1.8   5.5 --   3.6 12.7 14.5
Evanston Hospital, Evanston, IL 35 11.4   2.9   2.9   0.0 0.0 14.3 0.0   5.7 --   0.0   5.7   8.6
Rush-Presbyterian St. Luke’s 41 14.6   4.9   4.9   2.4 0.0 19.5 0.0 17.1 --   7.3   2.4 19.5
  Medical Center, Chicago, IL
Clarian Health Methodist Hospital, 55 18.2   7.3   3.6   0.0 1.8 16.4 0.0   7.3 --   3.6 10.9 12.7
  Indianapolis, IN
Washington University, 55 12.7 16.4 14.5   3.6 0.0 12.7 0.0   9.1 --   5.5 18.2 12.7
  St. Louis, MO
Henry Ford Health System, 60 21.7   8.3 10.0   3.3 0.0 10.0 0.0   8.3 --   6.7 15.0 10.0
  Detroit, MI
The Cleveland Clinic Foundation, 60 10.0 13.3 11.7   3.3 0.0 20.0 1.7 10.0 --   6.7 11.7 15.0
  Cleveland, OH
Temple University Hospital, 42   7.1 14.3   4.8   9.5 2.4 9.5 0.0   7.1 --   4.8   2.4   9.5
  Philadelphia, PA
Geisinger Medical Center, 49 30.6   8.2 12.2   0.0 0.0 20.4 0.0 20.4 -- 12.2 10.2 14.3
  Danville, PA
SUNY Health Science Center, 50 12.0   8.0   8.0   2.0 0.0 8.0 0.0   8.0 --   6.0 12.0   8.0
  Syracuse, NY
University of Rochester Medical
  Center, Rochester, NY 50 10.0 10.0 10.0   2.0 2.0 10.0 0.0   8.0 --   6.0   8.0 14.0
Columbia Presbyterian Medical 53 18.9   1.9   3.8   0.0 0.0 3.8 0.0   7.5 --   5.7   5.7   7.5
  Center, New York, NY
Dartmouth Hitchcock Medical 50   8.0   8.0   4.0   4.0 0.0 10.0 0.0   6.0 --   6.0   6.0 22.0
  Center, Lebanon, NH
Hartford Hospital, Hartford, CT 51 17.6   9.8   9.8   0.0 2.0 5.9 0.0   7.8 --   2.0 11.8 17.6
Beth Israel Deaconess Medical 41   9.8   4.9   2.4   2.4 0.0 14.6 0.0   9.8 --   2.4   7.3   9.8
  Center, Boston, MA
Children’s Hospital, Washington, DC 28 17.9 17.9 21.4   0.0 0.0 28.6 0.0 17.9 --   3.6   7.1 28.6
University of North Carolina 49 22.4 34.7 26.5 14.3 2.0 36.7 0.0 20.4 -- 16.3 16.3 46.9
  Hospital, Chapel Hill, NC
Dekalb Medical Center, 52 32.7 11.5 11.5   1.9 0.0 26.9 0.0 17.3 --   7.7   3.8 28.8
  Decatur, GA
University of Louisville Hospital, 48 22.9 10.4   4.2   8.3 0.0 20.8 0.0   6.3 --   2.1   6.3 18.8
  Louisville, KY
University of South Alabama, 58 17.2 24.1 17.2   6.9 0.0 37.9 0.0 13.8 -- 13.8 12.1 39.7
  Mobile, AL
Mount Sinai Medical Center, 27 18.5 33.3 25.9 22.2 0.0 29.6 0.0 29.6 -- 25.9   7.4 48.1
  Miami Beach, FL
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South and Southeast. The lowest overall rate of
ceftriaxone resistance was 2.9%; the highest was
48.1%. With erythromycin, overall rates of
resistance were 3.8% to 43.8%. With tetracy-
cline, chloramphenicol, and TMP/SMX, the rates
were 5.7% to 29.6%, 0.0% to 25.9%, and 11.9% to
63.2%, respectively. In general, the highest rates
of resistance with most antimicrobial classes
were observed in the same centers.
Among the 34 medical centers, 24 had
participated in a similar study 3 years before (4).
Because the sampling period, the nature of the
patients, and the test methods were the same,
resistance rates obtained with selected antimi-
crobial drugs were compared at the 24 centers for
the two study periods (Table 6). In 19 of 24
centers, penicillin resistance rates (intermediate
and resistant) increased by at least 2% during
the 3-year interval. In six cases, the rate of
increase was statistically significant (Table 6).
The number of centers in which rates of
resistance increased by >2% with other selected
antimicrobial drugs over the 3-year period were
ceftriaxone 13, erythromycin 21, tetracycline 20,
chloramphenicol 12, and TMP/SMX 16. In most
cases, resistance rates increased; however, with
certain antimicrobial agents (i.e., ceftriaxone,
TMP/SMX, and chloramphenicol), resistance
rates remained the same or decreased. Three
centers (Texas Children’s Hospital, UNC
Hospital, and the University of South Alabama
Medical Center) had statistically significant
increased rates of resistance to nearly every class
of antimicrobial drug.
Conclusions
A total of 1,601 clinical isolates of
S. pneumoniae obtained from November 1997 to
April 1998 from patients in 34 U.S. medical
centers were characterized with respect to the in
vitro activity of 23 antimicrobial drugs. The
overall rate of penicillin resistance was 29.5%
(17.4% with intermediate resistance; 12.1% fully
resistant). Penicillin, amoxicillin, and amoxicillin/
clavulanate had essentially equivalent MICs for
the pneumococcal isolates examined. Among the
cephalosporins tested, the rank order of activity
based on a comparison of MICs was ceftriaxone >
cefpodoxime = cefuroxime > cefprozil > cefixime >
cefaclor = loracarbef > ceftibuten. NCCLS has
developed MIC interpretive breakpoints for two
of these compounds, ceftriaxone and cefuroxime.
On the basis of these breakpoints, overall
resistance rates were 14.9% with ceftriaxone
(10.9% intermediate, 4.0% resistant) and 23.3%
with cefuroxime (1.3% intermediate and 22.0%
resistant). Although no NCCLS-approved
breakpoints have been developed for cefaclor,
loracarbef, and ceftibuten versus S. pneumoniae,
the high MICs we obtained with these drugs
indicate that they would be poor choices for
treating pneumococcal infections.
We observed a direct relationship between
penicillin activity and the activity of all the other
ß-lactam drugs we examined. This relationship,
which has been observed by others, results from
the principal mechanism of penicillin resistance
in  S. pneumoniae, alterations in penicillin
binding proteins (4-6). The same proteins to
which penicillin binds are necessary for the
expression of the activity of all other ß-lactam
antimicrobial drugs (8-11).
Among the macrolides examined, clarithro-
mycin was generally one dilution more active
than erythromycin, which in turn was one
dilution more active than azithromycin. How-
ever, since NCCLS MIC interpretive breakpoints
differ for these agents and given the actual
distribution of MICs, overall rates of resistance
for these three agents were similar (19.0%).
Two previous studies have indicated that
macrolide resistance with S. pneumoniae exists
primarily in one of two forms: strains with
altered ribosomal targets due to expression of the
ermAM gene and strains with an active efflux
pump due to expression of the mefE gene (13,14).
ErmAM-positive isolates have constitutive
expression of resistance and typically have high
levels of resistance to both clindamycin (MICs
 >8  µg/ml) and erythromycin (MICs  >64 µg/ml).
Efflux mutants are susceptible to clindamycin
(MICs <0.25 µg/ml) and typically have erythro-
mycin MICs 1 to 32 µg/ml.
In a recent survey in Canada, approximately
60% of macrolide-resistant strains of
S. pneumoniae appeared to be efflux mutants
(19). In our study, 214 (70.8%) of 302 macrolide-
resistant strains were characterized by the efflux
phenotype. When a random sample of 35 of these
isolates was examined by PCR, 31 (88.6%) lacked
the  ermAM gene but had the mefE gene
responsible for efflux. Among the remaining four
strains in this group that were characterized at a
molecular level, one was ermAM positive and
mefE negative, two were positive for both ermAM
and  mefE, and one was negative for all763 763 763 763 763 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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macrolide-resistance markers. Based on their
phenotype (i.e., erythromycin MICs  >64 µg/ml,
with clindamycin MICs >8 µg/ml), 83 (27.5%) of
the 302 macrolide-resistant strains appeared
to have constitutive expression of ermAM-
mediated methylation of ribosomal targets. All
38 randomly selected isolates from this group
were  ermAM positive; 12 were also mefE
positive by PCR.
Five macrolide-resistant strains were not
readily placed into either the efflux or the target
modification groups based on phenotype. Two
Table 6. Resistance rate comparison of selected antimicrobial drugs for 24 medical centers, by study period
Peni- Ceftria- Erythro- Tetra- Chloram- TMP/
No. of Study cillin xone mycin cycline phenicol SMX
Medical center isolates period % I % R % I % R % I % R % I % R % I % R % I % R
Children’s Hospital & Medical 37 1994-95 21.6 13.5   8.1   8.1 0.0   5.4 0.0 18.9 --   8.1 10.8 37.8
  Center, Seattle, WA 50 1997-98 26.0 12.0 10.0   8.0 0.0 30.0a 0.0 24.0 -- 10.0   8.0 34.0
Denver Health, Denver, CO 62 1994-95 11.3   3.2   1.6   0.0 0.0   3.2 0.0   3.2 --   0.0   6.5   9.7
26 1997-98   7.7   7.7 11.5   0.0 0.0   7.7 0.0 11.5 -- 11.5a   3.8 15.4
Good Samaritan Medical 57 1994-95 21.1 19.3 21.1   7.0 0.0 12.3 0.0 14.0 --   5.3 10.5 19.3
  Center, Phoenix, AZ 54 1997-98 11.1 29.6 24.1 11.1 0.0 35.2a 0.0 20.4 --   5.6 11.1 38.9
Texas Children’s Hospital, 63 1994-95   9.5 15.9   9.5   6.3 0.0 22.2 0.0   9.5 --   7.9   7.9 30.2
  Houston, TX 48 1997-98 39.6 25.0a 25.0 10.4a 0.0 43.8a 2.1 22.9a -- 14.6 20.8 41.7
Parkland Health & Hospital 58 1994-95   8.6 13.8   8.6   5.2 0.0   6.9 0.0   5.2 --   5.2 15.5 12.1
  System, Dallas, TX 36 1997-98 19.4 11.1 11.1   2.8 0.0 27.8a 0.0 22.2a -- 11.1 16.7 22.2
Mayo Clinic, Rochester, MN 35 1994-95   2.9 11.4   5.7   5.7 0.0   8.6 2.9   8.6 --   5.7   8.6 22.9
48 1997-98 16.7   6.3   6.3   4.2 0.0 20.8 2.1 10.4 --   6.3 10.4 16.7
Children’s Hospital, 65 1994-95 20.0 13.8   6.2   6.2 0.0 18.5 0.0   6.2 --   7.7   6.2 29.2
  Milwaukee, WI 55 1997-98 12.7   7.3   7.3   3.6 0.0 10.9 1.8   5.5 --   3.6 12.7 14.5
Evanston Hospital, 49 1994-95 10.2   4.1   6.1   2.0 0.0   8.2 0.0   4.1 --   4.1   4.1 16.3
  Evanston, IL 35 1997-98 11.4   2.9   2.9   0.0 0.0 14.3 0.0   5.7 --   0.0   5.7   8.6
Rush-Presbyterian St. Luke’s 41 1994-95 19.5 14.6   4.9 14.6 0.0 17.1 0.0   7.3 -- 12.2   9.8 29.3
 Medical Center, Chicago, IL 41 1997-98 14.6   4.9   4.9   2.4 0.0 19.5 0.0 17.1 --   7.3   2.4 19.5
Clarian Health Methodist 63 1994-95 17.5   3.2   6.3   1.6 0.0   7.9 0.0   3.2 --   1.6 14.3 14.3
  Hospital, Indianapolis, IN 55 1997-98 18.2   7.3   3.6   0.0 1.8 16.4 0.0   7.3 --   3.6 10.9 12.7
Washington University, 57 1994-95 19.6   5.4   8.8   3.5 0.0   8.9 0.0   7.1 --   5.4   7.1 12.5
  St. Louis, MO 55 1997-98 12.7 16.4 14.5   3.6 0.0 12.7 0.0   9.1 --   5.5 18.2 12.7
Henry Ford Health System, 63 1994-95 17.5 1.6   1.6   4.8 0.0   6.3 0.0   4.8 --   3.2   7.9 12.7
  Detroit, MI 60 1997-98 21.7   8.3 10.0   3.3 0.0 10.0 0.0   8.3 --   6.7 15.0 10.0
The Cleveland Clinic Foun- 42 1994-95   4.8 14.3   4.8   9.5 0.0 11.9 0.0   9.5 --   7.1 11.9 26.2
  dation, Cleveland, OH 60 1997-98 10.0 13.3 11.7   3.3 0.0 20.0 1.7 10.0 --   6.7 11.7 15.0
Temple University Hospital, 47 1994-95   2.1   0.0   2.1   0.0 0.0   2.1 0.0   0.0 --   0.0   4.3   4.3
  Philadelphia, PA 42 1997-98   7.1 14.3a   4.8   9.5a 2.4   9.5 0.0   7.1 --   4.8   2.4   9.5
Geisinger Medical Center, 57 1994-95 10.5 10.5   5.3   5.3 0.0   5.3 1.8   8.8 --   7.0   5.3 10.5
  Danville, PA 49 1997-98 30.6   8.2a 12.2   0.0 0.0 20.4a 0.0 20.4 -- 12.2 10.2 14.3
SUNY Health Science Center, 23 1994-95   8.7   0.0   0.0   0.0 0.0   8.7 0.0   4.3 --   0.0   4.3   4.3
  Syracuse, NY 50 1997-98 12.0   8.0   8.0   2.0 0.0   8.0 0.0   8.0 --   6.0 12.0   8.0
University of Rochester 58 1994-95   5.2   5.2   5.2   1.7 0.0   6.9 0.0 10.3 --   5.2   5.2 13.8
  Medical Ctr., Rochester, NY 50 1997-98 10.0 10.0 10.0   2.0 2.0 10.0 0.0   8.0 --   6.0   8.0 14.0
Columbia Presbyterian Medical 64 1994-95   6.3   6.3   4.7   4.7 0.0   4.7 0.0   3.1 --   0.0 10.9 10.9
  Center, New York, NY 53 1997-98 18.9   1.9   3.8   0.0 0.0   3.8 0.0   7.5 --   5.7   5.7   7.5
Hartford Hospital, 61 1994-95 3.31   4.9   1.6   4.9 0.0   3.3 0.0   0.0 --   0.0   0   8.2
  Hartford, CT 51 1997-98 17.6   9.8a   9.8   0.0 2.0   5.9 0.0   7.8a --   2.0 11.8 17.6
Children’s Hospital, 60 1994-95 16.7   6.7   5.0   3.3 0.0 13.3 0.0   3.3 --   0.0   6.7 15.0
  Washington, DC 28 1997-98 17.9 17.9 21.4   0.0 0.0 28.6 0.0 17.9a --   3.6   7.1 28.6
University of North Carolina 60 1994-95 21.7 10.0   8.3   3.3 0.0 10.0 0.0   8.3 --   6.7 16.7 25.0
  Hospital, Chapel Hill, NC 49 1997-98 22.4 34.7a 26.5 14.3a 2.0 36.7a 0.0 20.4 -- 16.3 16.3 46.9a
Dekalb Medical Center, 61 1994-95 16.4 19.7 13.1 13.1 0.0 23.0 0.0 11.5 --   9.8   1.6 27.9
  Decatur, GA 52 1997-98 32.7 11.5 11.5   1.9 0.0 26.9 0.0 17.3 --   7.7   3.8 28.8
University of South 68 1994-95 13.2   7.4   5.9   2.9 1.5 14.7 0.0   4.4 --   0.0   2.9 25.0
  Alabama, Mobile, AL 58 1997-98 17.2 24.1a 17.2   6.9a 0.0 37.9a 0.0 13.8 -- 13.88 12.1 39.7a
Mount Sinai Medical Center, 17 1994-95 29.4 23.5   5.9 17.6 0.0   5.9 0.0 17.6 -- 11.8 23.5 23.5
  Miami Beach, FL 27 1997-98 18.5 33.3 25.9 22.2 0.0 29.6 0.0 29.6 -- 25.9   7.4 48.1
aStatistically significant change in resistance rates (I + R) from 1994-95 to 1997-98; p value:50.05.
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strains with high-level clindamycin resistance
but erythromycin MICs 2 and 32 µg/ml were
ermAM positive but mefE negative. Three
strains with erythromycin MICs >64 had
clindamycin MICs 0.5, 1, and 4 µg/ml. One of
these strains, which had a clindamycin MIC of 4
and a high erythromycin MIC, appeared to be an
efflux mutant since it was mefE positive but
ermAM negative. The mechanism of resistance
in the last two isolates in this group is unclear.
Both isolates were negative by PCR for ermAM
and mefE, as well as other genetic markers for
macrolide and lincosamide resistance in gram-
positive bacteria.
Several conclusions can be drawn from these
observations. Macrolide resistance in
S. pneumoniae is nearly always characterized
either by efflux or ribosomal target modifica-
tions. The phenotype of isolates in both
categories is highly predictable. Efflux mutants
usually have erythromycin MICs 1 - 32 µg/ml
and clindamycin MICs <0.25 µg/ml. Target
modified strains are characterized by constitu-
tive expression of resistance and typically have
erythromycin MICs  >64 µg/ml and clindamycin
MICs  >8 µg/ml. Although rare exceptions to
these patterns exist, clindamycin activity, as
assessed by an MIC determination, is a reliable
indicator of the nature of macrolide resistance.
These results show that therapeutic efficacy
can be predicted for patients with pneumococcal
infections who are treated with macrolides.
Using current NCCLS interpretive criteria, 18%
to 19% of clinical isolates of S. pneumoniae in the
United States would be categorized as resistant.
Approximately three-fourths of the resistant
strains, however, are efflux mutants and have
mid-range resistant macrolide MICs. Patients
infected with mefE versus ermAM-positive
strains of S. pneumoniae may differ in their
response to macrolide therapy. The answer to
this important question would define true
clinical rates of macrolide resistance. If mefE
strains respond to therapy with macrolide drugs,
then true macrolide resistance rates may not be
18% to 19%, but closer to 4% to 5%, and high-
level clindamycin MICs could be used to
accurately identify strains highly resistant to
macrolide drugs.
Multidrug resistance was noted with 16.0%
of 1,601 isolates, a substantial increase over the
9.1% prevalence of multidrug resistant
S. pneumoniae reported in our 1994-95 study (4).
Among multidrug resistant strains, four resis-
tance patterns were the most common: penicillin
and TMP/SMX (n = 111); penicillin, macrolide, and
chloramphenicol (n = 75); penicillin, macrolide,
tetracycline, and TMP/SMX (n = 57); and
penicillin, macrolide, tetracycline, TMP/SMX,
and chloramphenicol (n = 87). No obvious
clustering of multidrug resistant strains was
observed in either individual medical centers or
geographic regions.
That we found resistance to ß-lactam
antimicrobial agents and numerous non-ß-
lactam agents in the same organism is of
interest. The mechanisms of resistance to the
different antimicrobial classes are distinct and
do not appear to be linked genotypically. One
explanation, therefore, for the increasing
prevalence of multidrug resistant strains is
clonal spread of organisms resistant to more
than one class of antimicrobial drugs. Under
such circumstances, regardless of the antimicro-
bial drug used to select for resistance, multidrug
resistant organisms may become more preva-
lent. Clonal spread warrants further study using
appropriate techniques for establishing clonal
relationships among multiple geographically
distinct isolates of S. pneumoniae.
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Appendix
Isolates were frozen at -70°C at the University of Iowa
College of Medicine until further characterization. After two765 765 765 765 765 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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subcultures, the identity of isolates was confirmed
as  S. pneumoniae by conventional tests and criteria. MICs
were determined in Mueller-Hinton broth supplemented
with 3% lysed horse blood, according to the broth
microdilution method recommended by the National
Committee for Clinical Laboratory Standards (NCCLS) (15).
Microdilution trays (final volume 100 µl per well) were
inoculated with approximately 5 x 105 colony-forming units
(CFU)/ml (final concentration) of test organism and incubated
22 to 24 hours at 35°C in ambient air before MICs were
determined.
S. pneumoniae ATCC 49619 and Haemophilus influenzae
ATCC 49247, ATCC 49766, and ATCC 10211 were used as
controls. Calculations of the percentages of isolates resistant
to individual agents were based on the most recent MIC
interpretive criteria published by NCCLS (16).
Selected isolates were examined for mutations in the
quinolone resistance-determining region of the parC and par
E genes encoding the C and E subunits of topoisomerase IV,
respectively, and the quinolone resistance-determining
region of the gyrA gene encoding for the A subunit of DNA
gyrase. Polymerase chain reaction (PCR) amplification with
subsequent sequencing of PCR products was done by using
the method and primers described by Pan et al. (17) and
Perichon et al. (18). Other isolates were screened for various
macrolide resistance determinants by PCR amplification as
described by Shortridge et al. (13). Primers were chosen by
using Oligo 5.0 software (NBI, Plymouth, MI) from sequences
deposited in Genbank. Strains negative for both mefE (efflux
mutants) and ermAM (ribosome methylase) were character-
ized further for the presence of other methylase genes (ermA
and ermC), erythromycin esterase (ereA and ereB), MS efflux
(msrA) and the gene for lincosamide resistance (linA), again
as described by Shortridge et al. (13).
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